TY  - JOUR
A1  - Lillich, Felix F.
A1  - Imig, John D.
A1  - Proschak, Ewgenij
T1  - Multi-target approaches in metabolic syndrome
T2  - Frontiers in Pharmacology
N2  - Metabolic syndrome (MetS) is a highly prevalent disease cluster worldwide. It requires polypharmacological treatment of the single conditions including type II diabetes, hypertension, and dyslipidemia, as well as the associated comorbidities. The complex treatment regimens with various drugs lead to drug-drug interactions and inadequate patient adherence, resulting in poor management of the disease. Multi-target approaches aim at reducing the polypharmacology and improving the efficacy. This review summarizes the medicinal chemistry efforts to develop multi-target ligands for MetS. Different combinations of pharmacological targets in context of in vivo efficacy and future perspective for multi-target drugs in MetS are discussed.
KW  - metabolic sydrome
KW  - polypharmacology
KW  - multi-target drug
KW  - peroxisome prolifer ators-activated receptor-γ
KW  - soluble epoxide hydrolase
KW  - farnesoid X receptor
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62398
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-623988
SN  - 1663-9812
N1  - EP was supported by the German Research Foundation (DFG, Heisenberg-Professur PR1405/7-1 and SFB 1039 TP A07). JI was supported by a National Institute of Health (NIH) grant (DK103616) and Ralph and Marian Falk Medical Research Trust Bank of America, N.A., Trustee grant.
VL  - 11
IS  - art. 554961
SP  - 1
EP  - 18
PB  - Frontiers Media
CY  - Lausanne
ER  -